Assenagon Asset Management S.A. Sells 155,723 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Assenagon Asset Management S.A. reduced its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,312,479 shares of the company's stock after selling 155,723 shares during the period. Assenagon Asset Management S.A. owned 2.49% of Stoke Therapeutics worth $16,130,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Quest Partners LLC purchased a new position in Stoke Therapeutics in the second quarter valued at about $29,000. Nisa Investment Advisors LLC grew its stake in shares of Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock valued at $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics in the second quarter worth approximately $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics during the first quarter valued at approximately $141,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have recently commented on STOK. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. Leerink Partners started coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. Finally, Wedbush restated an "outperform" rating and issued a $17.00 target price on shares of Stoke Therapeutics in a report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and a consensus price target of $20.83.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK traded down $0.14 during trading hours on Friday, hitting $11.91. 238,514 shares of the company's stock were exchanged, compared to its average volume of 776,231. The company's 50-day moving average price is $13.48 and its 200-day moving average price is $13.69. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.58. The stock has a market capitalization of $620.76 million, a price-to-earnings ratio of -4.94 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.11. The company had revenue of $4.83 million during the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, research analysts expect that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the business's stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.